Great Point Partners LLC Trims Stock Holdings in Jasper Therapeutics, Inc. (NASDAQ:JSPR)

Great Point Partners LLC lessened its position in shares of Jasper Therapeutics, Inc. (NASDAQ:JSPR) by 1.4% during the 2nd quarter, Holdings Channel reports. The firm owned 402,015 shares of the company’s stock after selling 5,535 shares during the quarter. Jasper Therapeutics comprises 1.7% of Great Point Partners LLC’s portfolio, making the stock its 22nd largest holding. Great Point Partners LLC’s holdings in Jasper Therapeutics were worth $9,126,000 as of its most recent SEC filing.

Other hedge funds have also modified their holdings of the company. Rhumbline Advisers purchased a new stake in Jasper Therapeutics in the second quarter valued at approximately $300,000. Virtu Financial LLC purchased a new stake in shares of Jasper Therapeutics in the 1st quarter valued at $306,000. American Century Companies Inc. increased its stake in shares of Jasper Therapeutics by 27.1% in the second quarter. American Century Companies Inc. now owns 14,204 shares of the company’s stock worth $322,000 after acquiring an additional 3,032 shares during the period. Concurrent Investment Advisors LLC purchased a new position in shares of Jasper Therapeutics during the first quarter worth $599,000. Finally, Bank of New York Mellon Corp acquired a new position in Jasper Therapeutics during the second quarter valued at $740,000. 79.85% of the stock is owned by institutional investors and hedge funds.

Jasper Therapeutics Stock Performance

NASDAQ:JSPR opened at $21.54 on Tuesday. The company has a fifty day moving average of $19.78 and a two-hundred day moving average of $22.65. Jasper Therapeutics, Inc. has a fifty-two week low of $4.00 and a fifty-two week high of $31.01. The stock has a market capitalization of $324.40 million, a PE ratio of -3.83 and a beta of 2.22.

Jasper Therapeutics (NASDAQ:JSPR) last issued its quarterly earnings results on Tuesday, August 13th. The company reported ($0.97) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.09) by $0.12. Research analysts forecast that Jasper Therapeutics, Inc. will post -4.16 earnings per share for the current year.

Analyst Ratings Changes

Several equities research analysts have weighed in on JSPR shares. HC Wainwright reaffirmed a “buy” rating and set a $65.00 price target on shares of Jasper Therapeutics in a research report on Tuesday, August 13th. Royal Bank of Canada reduced their price target on Jasper Therapeutics from $70.00 to $68.00 and set an “outperform” rating for the company in a research report on Wednesday, August 14th. Evercore ISI restated an “outperform” rating and issued a $65.00 price objective on shares of Jasper Therapeutics in a research report on Monday, August 26th. JMP Securities initiated coverage on shares of Jasper Therapeutics in a report on Monday, September 9th. They set an “outperform” rating and a $70.00 target price for the company. Finally, BTIG Research initiated coverage on shares of Jasper Therapeutics in a report on Monday, July 8th. They set a “buy” rating and a $90.00 price target on the stock. Ten equities research analysts have rated the stock with a buy rating, According to MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus price target of $73.00.

About Jasper Therapeutics

Jasper Therapeutics, Inc, a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy.